Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 6.16  0.02  0.32%   
About 68% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at news.google.com         
Y-mAbs Therapeutics, Inc. Shares Sold by Point72 Asset Management L.P. - MarketBeat
Google News at Macroaxis
over a month ago at simplywall.st         
We Think Y-mAbs Therapeutics Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a month ago at globenewswire.com         
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American So...
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American So...
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
Macroaxis News
over a month ago at investing.com         
Y-mAbs Therapeutics SWOT analysis innovative cancer therapy stock faces growth hurdles
Investing News at Macroaxis
over a month ago at thelincolnianonline.com         
Y-mAbs Therapeutics, Inc. Receives 21.38 Average Price Target from Analysts
news
over a month ago at finance.yahoo.com         
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
Yahoo News
over a month ago at globenewswire.com         
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
Gurufocus Stories at Macroaxis
over a month ago at benzinga.com         
Disposition of 722 shares by Ber Gerard of Y MAbs at 12.0 subject to Rule 16b-3
benzinga news
over a month ago at benzinga.com         
Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement
benzinga news
over a month ago at news.google.com         
Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat
Google News at Macroaxis
over two months ago at simplywall.st         
The Market Doesnt Like What It Sees From Y-mAbs Therapeutics, Inc.s Revenues Yet As Shares Tumble 26
Simply Wall St News at Macroaxis
over two months ago at finance.yahoo.com         
Institutional investors in Y-mAbs Therapeutics, Inc. lost 25 percent last week but have reaped the b...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
What To Expect From Y-mAbs Therapeutics Inc Q3 2024 Earnings
11/07/2024
2
Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat
11/21/2024
3
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
11/27/2024
4
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
12/06/2024
5
Y-mAbs Therapeutics, Inc. Shares Sold by Point72 Asset Management L.P. - MarketBeat
12/11/2024
6
Were Hopeful That Y-mAbs Therapeutics Will Use Its Cash Wisely
12/20/2024
7
Insider Trading
01/06/2025
8
Correcting Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
01/10/2025
9
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
01/13/2025

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
CEOs Directory
Screen CEOs from public companies around the world
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stocks Directory
Find actively traded stocks across global markets